Fennec Pharmaceuticals Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 2.8, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the Fennec Pharmaceuticals Inc in Jun 30 2026 quarter, has decreased to 130 days, compared to 141 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 141 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1188, from overall ranking in the first quarter 2026 at 2663.

What is Receivable Turnover Ratio?
What is Fennec Pharmaceuticals Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

FENC Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	32.93 %	21.45 %	80.23 %	49.85 %	42.15 %
Y / Y Revenue Change	85.18 %	72.64 %	73.84 %	78.69 %	32.91 %
Receivable Turnover Ratio (TTM)	2.8	2.59	2.36	2.38	2.27
FENC's Total Ranking	# 1188	# 2663	# 2706	# 0	# 0
Accounts Receivable average collection period days	130	141	154	153	161
Seq. Receivable Change	24.01 %	-19.2 %	20.05 %	10.52 %	13.3 %
Seq. Revenue Change	18.31 %	9.66 %	10.55 %	29.11 %	10.3 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 6
Healthcare Sector	# 142
Overall Market	# 1188

Receivable Turnover Ratio Statistics
High	Average	Low
2.41	1.07	0.53
(Mar 31 2015)		(Mar 31 2016)

FENC Company Profile • Back to FENC Efficiency Comparisons • Compare FENC Receivables Turnover Ratio to its Competitors

Financial Statements
Fennec Pharmaceuticals Inc 's Accounts Receivable	$ 23 Millions	Visit FENC's Balance sheet
Fennec Pharmaceuticals Inc 's Sales TTM	$ 59 Millions	Visit FENC's Income Statement
Sources of FENC's Revenues		Visit FENC's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
FENC's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
FENC's Growth Rates	FENC's Roa	FENC's Inventory Turnover Ratio	FENC's Dividend Comparisons
FENC's Profitability Ratios	FENC's Roi	FENC's Asset Turnover Ratio	FENC's Dividend Growth
FENC's Valuation Ratios	FENC's Roe	FENC's Financial Strength Ratios	FENC's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Tandem Diabetes Care Inc	6.98	$ 1,037.302 Millions	$ 148.542 Millions
Sutro Biopharma Inc	6.98	$ 45.702 Millions	$ 6.545 Millions
Beyond Air Inc	6.98	$ 6.677 Millions	$ 0.957 Millions
Myriad Genetics Inc	6.91	$ 805.900 Millions	$ 116.650 Millions
Medpace Holdings Inc	6.91	$ 2,782.288 Millions	$ 402.873 Millions
Ceribell Inc	6.90	$ 101.804 Millions	$ 14.749 Millions
Stryker Corp	6.89	$ 25,837.000 Millions	$ 3,749.000 Millions
Syndax Pharmaceuticals Inc	6.88	$ 252.004 Millions	$ 36.646 Millions
Tarsus Pharmaceuticals Inc	6.85	$ 606.331 Millions	$ 88.512 Millions
Neuropace Inc	6.85	$ 98.620 Millions	$ 14.398 Millions
Nephros Inc	6.83	$ 21.686 Millions	$ 3.173 Millions
Opko Health Inc	6.79	$ 587.896 Millions	$ 86.589 Millions
Atara Biotherapeutics Inc	6.79	$ 6.452 Millions	$ 0.950 Millions
Delcath Systems Inc	6.77	$ 94.058 Millions	$ 13.899 Millions
Moderna Inc	6.76	$ 2,228.000 Millions	$ 329.500 Millions
Carlisle Companies Incorporated	6.76	$ 5,097.000 Millions	$ 754.025 Millions
Rapid Micro Biosystems Inc	6.76	$ 34.545 Millions	$ 5.111 Millions
Universal Health Services Inc	6.75	$ 18,114.487 Millions	$ 2,683.492 Millions
3m Company	6.72	$ 25,180.000 Millions	$ 3,747.750 Millions
Phibro Animal Health Corporation	6.70	$ 1,516.861 Millions	$ 226.555 Millions
Envista Holdings Corporation	6.69	$ 2,856.400 Millions	$ 427.250 Millions
Eton Pharmaceuticals Inc	6.67	$ 105.279 Millions	$ 15.783 Millions
Ufp Technologies Inc	6.65	$ 632.042 Millions	$ 94.976 Millions
Aspira Women s Health inc	6.65	$ 9.029 Millions	$ 1.358 Millions
Bionano Genomics Inc	6.62	$ 30.176 Millions	$ 4.556 Millions
Livanova Plc	6.62	$ 1,470.112 Millions	$ 222.035 Millions
Agilon Health Inc	6.61	$ 5,920.015 Millions	$ 895.120 Millions
Liquidia Corporation	6.61	$ 450.907 Millions	$ 68.198 Millions
Beone Medicines Ltd	6.58	$ 6,128.238 Millions	$ 930.639 Millions
Embecta Corp	6.57	$ 1,019.700 Millions	$ 155.125 Millions

Date modified: 2026-10-15T05:23:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.